EAST BRUNSWICK, N.J., May 29, 2009 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) announced today that six abstracts (two oral presentations and four posters) about the Company's product candidate KRYSTEXXA(tm) (pegloticase) will be presented at the European League Against Rheumatism (EULAR) 2009 Annual Congress June 10-13 in Copenhagen, Denmark addressing various aspects of treatment failure gout. Treatment failure gout occurs in patients with gout who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with urate-lowering therapy at the maximum medically appropriate dose or for whom those drugs are contraindicated.

The first oral presentation will discuss complete tophus resolution with KRYSTEXXA defined as a 100 percent decrease in measured tophus area, as observed during Savient's two replicate Phase 3 Gout Outcomes and Urate Lowering Therapy (GOUT 1 and GOUT 2) clinical trials. The second oral presentation will address data suggesting that the health-related quality of life in patients with treatment failure gout is significantly compromised and is comparable to other severe chronic conditions.

The four poster presentations will address data from Savient's Phase 3 clinical trial of KRYSTEXXA for treatment failure gout. Data on patients' quality of life following KRYSTEXXA treatment, results of a global internet-based quantitative market research survey in hyperuricemia and gout and clinical practice patterns will be presented.

Oral presentation details are as follows:

    -- Reduction of Tophus Size with Pegloticase (PGL) in Treatment
       Failure Gout (TFG): Results from GOUT1 and GOUT2 (HSB Baraf
       et al, Abstract #OP-0047, June 11, 2009, 10:15 a.m., Auditorium 2) 
    -- Health Related Quality-of-Life (HRQOL) of Patients with
       Treatment Failure Gout (TFG) is Poor and Comparable to that
       in Other Severe Chronic Conditions (V Strand, Abstract
       #OP-0291, June 13, 2009, 8:45 a.m., Hall A3)

Poster presentation details are as follows:

    -- Efficacy and Safety of Intravenous Pegloticase (PGL) in
       Treatment Failure Gout (TFG): Results from GOUT1 and GOUT2
       (J Sundy et al, Abstract #THU0446, June 11, 2009, 11:45 a.m.,   
       Bella Center)
    -- Clinical Manifestations of Treatment Failure Gout (TFG) in
       Four independent Cohorts Abstract. (R.